NanoCarrier Co., Ltd. AI Stock Analysis
Want to see JP:4571 full AI Analyst Report?
NanoCarrier Co., Ltd. (4571) AI Stock Analysis
NanoCarrier Co., Ltd.
(TSE/TYO:4571)
NanoCarrier scores at the bottom of the range, driven primarily by very weak financials: continuous losses, negative operating and free cash flow, an equity base that has halved in five years, and rising debt that signals dependence on further capital raises. Technicals reinforce the caution, with the share price well below all key moving averages and a deeply negative MACD confirming a persistent downtrend. Valuation provides no cushion, as earnings are negative and no dividend is paid. The only mitigating factors are improving loss and cash-burn trends plus a projected ~50% FY2026 revenue rebound, making this a high-risk, speculative holding whose outcome hinges on pipeline success rather than current financial performance.
NanoCarrier Co., Ltd. (4571) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 6.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 710.50K
- Price to Earnings (P/E)
- -4.5
- Beta (1Y)
- 0.96
- Revenue Growth
- 48.92%
- EPS Growth
- -46.91%
- Country
- Japan
- Employees
- 23
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
NanoCarrier Co., Ltd. Business Overview & Revenue Model
Company Description
Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 P...
NanoCarrier Co., Ltd. Financial Statement Overview
Summary
Very weak fundamentals. The income statement (15) shows persistent losses, multi-year revenue decline to ¥109M in FY2025 and deeply negative net margins, despite a projected ~50% revenue rebound to ¥174M and narrowing EBIT losses in FY2026. The balance sheet (35) is eroding: equity has fallen from ¥7.5B to a projected ¥3.6B, total assets have contracted, and debt has risen to ¥1.6B (D/E 0.45), though leverage remains manageable. Cash flow (18) is the biggest concern, with negative operating and free cash flow in every period and full dependence on external financing, only partially offset by cash burn roughly halving since FY2022.
Income Statement
15Very NegativeBalance Sheet
35NegativeCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 202.50M | 174.50M | 108.52M | 135.51M | 202.19M | 264.03M |
| Gross Profit | 179.88M | 153.29M | 78.17M | 110.96M | 159.60M | 220.88M |
| EBITDA | -1.00B | -892.12M | -832.57M | -776.41M | -1.30B | -1.87B |
| Net Income | -1.02B | -943.88M | -835.38M | -780.00M | -1.31B | -1.88B |
Balance Sheet | ||||||
| Total Assets | 5.24B | 5.91B | 4.00B | 5.07B | 5.78B | 7.14B |
| Cash, Cash Equivalents and Short-Term Investments | 4.22B | 4.91B | 3.51B | 4.28B | 4.44B | 5.95B |
| Total Debt | 1.20B | 1.60B | 540.24M | 1.11B | 1.11B | 1.15B |
| Total Liabilities | 1.92B | 2.34B | 1.26B | 1.65B | 1.53B | 1.57B |
| Stockholders Equity | 3.31B | 3.57B | 2.74B | 3.42B | 4.25B | 5.57B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 0 | 0 | -585.08M | -1.09B | -1.76B |
| Operating Cash Flow | 0 | -816.67M | -401.62M | -585.08M | -1.09B | -1.75B |
| Investing Cash Flow | 0 | 2.26B | 587.53M | 793.01M | 1.21B | -244.13M |
| Financing Cash Flow | 0 | 2.22B | -568.77M | 3.73M | 32.20M | 1.15B |
NanoCarrier Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4571, the sentiment is Negative. The current price of 71.00 is below the 20-day moving average (MA) of 74.90, below the 50-day MA of 86.54, and below the 200-day MA of 118.78, indicating a bearish trend. The MACD of -4.97 indicates Positive momentum. The RSI at 39.31 is Neutral, neither overbought nor oversold. The STOCH value of 25.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4571.
NanoCarrier Co., Ltd. Peers Comparison
Overall Rating
JP:458855Neutral
JP:458349Neutral
JP:488847Neutral
JP:456445Neutral
JP:456342Neutral
JP:457137Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | JPY 225.09B | -138.17 | ― | ― | 1748.97% | 35.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | JPY 6.14B | -6.03 | ― | ― | -13.40% | 7.50% | |
| 47Neutral | JPY 16.43B | -15.96 | ― | ― | -69.92% | -411.54% | |
| 45Neutral | JPY 6.12B | -6.52 | -42.81% | ― | -25.56% | 17.01% | |
| 42Neutral | JPY 9.90B | -1.77 | -558.92% | ― | 19.67% | 84.06% | |
| 37Underperform | JPY 6.37B | -4.46 | -39.57% | ― | 48.92% | -46.91% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4571 | NanoCarrier Co., Ltd. | 71.00 | -79.00 | -52.67% | |
| JP:4563 | AnGes | 25.00 | -50.00 | -66.67% | |
| JP:4564 | OncoTherapy Science, Inc. | 15.00 | -6.00 | -28.57% | |
| JP:4583 | Chiome Bioscience Inc. | 78.00 | -47.00 | -37.60% | |
| JP:4588 | Oncolys BioPharma, Inc. | 7540.00 | 6523.00 | 641.40% | |
| JP:4888 | STELLA PHARMA CORPORATION | 460.00 | 206.00 | 81.10% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
